Dianthus (DNTH) Director Read Simon Exercises Options, Sells Shares

What Happened

• Read Simon, a director of Dianthus Therapeutics (DNTH), exercised 2,777 option shares on 2026-08-10 at an exercise price of $18.36 (total cost $50,986). The same day he sold the 2,777 shares in multiple open-market transactions for aggregate proceeds of approximately $304,232 (sales priced roughly $106.50–$111.80). A related derivative line shows the option conversion of 2,777 shares (reported at $0), consistent with an exercise followed by immediate sale (cashless exercise).

Key Details

• Transaction date: August 10, 2026; Form 4 filed August 11, 2026 (timely).
• Exercise: 2,777 shares @ $18.36 = $50,986 (code M).
• Sales: total 2,777 shares sold across multiple trades for total proceeds ≈ $304,232 (codes S); sale prices reported in weighted-average lots: $107.11, $108.17, $108.95, $109.96, $111.05, $111.77 (individual price ranges provided in footnotes, overall ~$106.50–$111.80).
• Net cash (proceeds minus exercise cost): ≈ $253,246.
• Shares owned after transaction: not disclosed in the provided excerpt of the Form 4.
• Notable footnotes: transaction executed under a Rule 10b5-1 trading plan adopted May 8, 2026 (F1). Several sale entries are reported as weighted averages with price ranges; the filer will supply per-share breakdown on request (F2–F7). Footnote F8 describes the original option vesting schedule (one‑third each year over three years).

Context

• This appears to be a same‑day exercise and sale (cashless), a common way for insiders to convert vested options to cash and cover exercise/tax costs; it is generally routine and does not necessarily signal a change in the insider’s view of the company. The transaction was completed under a pre-established 10b5-1 plan, which automates timing of sales.